This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
lung injury | 1046 |
acute lung | 653 |
acute respiratory | 464 |
respiratory distress | 366 |
distress syndrome | 346 |
ali ards | 313 |
mechanical ventilation | 242 |
stem cells | 224 |
epithelial cells | 202 |
intensive care | 189 |
induced ali | 183 |
septic shock | 168 |
lung tissue | 159 |
respiratory failure | 155 |
induced lung | 145 |
critically ill | 130 |
growth factor | 126 |
severe sepsis | 126 |
inflammatory response | 123 |
gene expression | 122 |
induced acute | 112 |
control group | 109 |
lung tissues | 107 |
mg kg | 106 |
pulmonary edema | 104 |
endothelial cells | 101 |
lung inflammation | 98 |
vascular permeability | 95 |
mesenchymal stem | 93 |
stem cell | 91 |
endothelial cell | 89 |
apache ii | 88 |
bone marrow | 87 |
care unit | 87 |
ill patients | 87 |
inflammatory cytokines | 87 |
like receptor | 85 |
alveolar epithelial | 83 |
alveolar macrophages | 83 |
progenitor cells | 80 |
animal models | 80 |
vascular endothelial | 73 |
oleic acid | 71 |
critical care | 71 |
airway epithelial | 70 |
necrosis factor | 70 |
liver i | 70 |
ards patients | 66 |
nitric oxide | 65 |
tumor necrosis | 64 |
human lung | 64 |
bronchoalveolar lavage | 63 |
hospital mortality | 62 |
patients admitted | 62 |
ttp ko | 61 |
immune response | 60 |
respiratory syndrome | 59 |
protein kinase | 59 |
challenged ttp | 59 |
severe acute | 58 |
mortality rate | 57 |
present study | 57 |
risk factors | 57 |
stem progenitor | 57 |
significantly higher | 55 |
activated protein | 54 |
organ dysfunction | 54 |
inflammatory mediators | 54 |
type ii | 54 |
mechanically ventilated | 54 |
association studies | 53 |
innate immune | 53 |
converting enzyme | 53 |
cell types | 53 |
epithelial cell | 53 |
clinical trials | 52 |
organ failure | 52 |
endothelial barrier | 52 |
icu stay | 51 |
inflammatory responses | 51 |
endothelial growth | 51 |
mouse model | 51 |
two groups | 51 |
lung epithelial | 50 |
nlrp inflammasome | 50 |
ng ml | 50 |
lps administration | 50 |
day mortality | 49 |
cord uid | 48 |
proinflammatory cytokines | 48 |
doc id | 48 |
icu admission | 47 |
ventilated patients | 47 |
human airway | 46 |
signaling pathways | 45 |
significant differences | 45 |
oxidative stress | 45 |
important role | 45 |
ml kg | 44 |
tlr signaling | 44 |
barrier function | 44 |
immune responses | 43 |
mortality rates | 43 |
pulmonary vascular | 43 |
ii score | 43 |
immune cells | 42 |
significantly reduced | 42 |
tidal volume | 41 |
lps challenge | 41 |
renal failure | 41 |
multiple organ | 41 |
time point | 40 |
alveolar epithelium | 40 |
gas exchange | 39 |
derived organoids | 39 |
nuclear factor | 39 |
blood pressure | 39 |
type i | 39 |
performed using | 38 |
rat model | 38 |
granule content | 38 |
differentially expressed | 38 |
pao fio | 38 |
septic patients | 38 |
smoke inhalation | 38 |
lavage fluid | 37 |
significantly increased | 37 |
statistical analysis | 37 |
icu mortality | 36 |
bal fluid | 36 |
protein expression | 36 |
signal transduction | 36 |
infl uence | 36 |
inflammatory cells | 36 |
fluid clearance | 36 |
signaling pathway | 36 |
barrier dysfunction | 35 |
pulmonary fibrosis | 35 |
lung disease | 35 |
clinical trial | 35 |
statistically significant | 35 |
extended data | 35 |
injury induced | 35 |
infl ammatory | 35 |
cystic fibrosis | 34 |
inflammatory lung | 34 |
arterial blood | 34 |
protein levels | 34 |
lps group | 34 |
protective effect | 34 |
gene therapy | 34 |
inflammatory cytokine | 34 |
higher mortality | 34 |
syndrome coronavirus | 33 |
organoids derived | 33 |
ec barrier | 33 |
nebulised heparin | 33 |
western blot | 33 |
ko mice | 33 |
virus infection | 33 |
airway epithelium | 33 |
protective effects | 33 |
gene transfer | 33 |
reperfusion injury | 33 |
influenza virus | 33 |
mean age | 33 |
rat lung | 32 |
previous studies | 32 |
adult respiratory | 31 |
cardiac surgery | 31 |
cohort study | 31 |
immune system | 31 |
nalp inflammasome | 31 |
lung diseases | 31 |
lung cancer | 30 |
oxide synthase | 30 |
critical role | 30 |
may also | 30 |
significant difference | 30 |
cytokine storm | 30 |
derived evs | 30 |
adult patients | 30 |
angiotensin ii | 30 |
genetic variations | 30 |
alveolar type | 30 |
alveolar fluid | 29 |
previously described | 29 |
barrier enhancement | 29 |
barrier integrity | 29 |
novel coronavirus | 29 |
cell death | 29 |
dendritic cells | 29 |
body weight | 29 |
significantly lower | 29 |
intestinal organoids | 29 |
pluripotent stem | 29 |
smooth muscle | 29 |
murine model | 29 |
alveolar space | 29 |
pulmonary inflammation | 29 |
highly pathogenic | 29 |
time points | 29 |
logistic regression | 28 |
reactive oxygen | 28 |
ali model | 28 |
sodium transport | 28 |
room temperature | 28 |
cytokine production | 28 |
data suggest | 28 |
ttp myeko | 28 |
lung organoids | 27 |
clinical studies | 27 |
ischemia reperfusion | 27 |
expressed genes | 27 |
observational study | 27 |
three groups | 27 |
controlled trial | 27 |
infl ammation | 27 |
respiratory tract | 27 |
heart failure | 27 |
innate immunity | 27 |
challenged wt | 27 |
thermo fisher | 27 |
light chain | 26 |
icu patients | 26 |
genetic polymorphisms | 26 |
treated mice | 26 |
lung endothelial | 26 |
hemorrhagic shock | 26 |
cells via | 26 |
care units | 26 |
systemic inflammation | 26 |
blood samples | 26 |
binding protein | 26 |
lung vascular | 26 |
noninfluenza group | 26 |
cell barrier | 25 |
cell signaling | 25 |
high mortality | 25 |
myosin light | 25 |
results showed | 25 |
inflammasome activation | 25 |
dry weight | 25 |
blood gas | 25 |
recent studies | 25 |
therapeutic potential | 25 |
transcription factor | 25 |
pulmonary hypertension | 25 |
plasminogen activator | 25 |
authors declare | 25 |
negative regulator | 25 |
control mice | 25 |
molecular mechanisms | 25 |
analysis showed | 25 |
myocardial infarction | 24 |
trauma patients | 24 |
proinflammatory cytokine | 24 |
systematic review | 24 |
fish oil | 24 |
alveolar damage | 24 |
cell proliferation | 24 |
edema fluid | 24 |
survival rate | 24 |
viral infection | 24 |
united states | 24 |
growth factors | 24 |
cell apoptosis | 24 |
adhesion molecule | 24 |
systemic inflammatory | 24 |
epithelial barrier | 23 |
lung inflammatory | 23 |
induced inflammation | 23 |
increased mortality | 23 |
inflammatory diseases | 23 |
results suggest | 23 |
stimulating factor | 23 |
commonly used | 23 |
amino acid | 23 |
critical illness | 23 |
oxygen species | 23 |
fatty acids | 23 |
injured lung | 23 |
progenitor cell | 23 |
likely diagnosis | 23 |
stromal cells | 23 |
cell lines | 23 |
coronavirus disease | 23 |
airway epithelia | 23 |
heart rate | 23 |
mpo activity | 23 |
pulmonary disease | 23 |
pulmonary microvascular | 23 |
increased levels | 22 |
ex vivo | 22 |
map kinase | 22 |
clinical characteristics | 22 |
derived stem | 22 |
macrophage migration | 22 |
injured lungs | 22 |
host response | 22 |
chain kinase | 22 |
inhibitory factor | 22 |
blood cells | 22 |
increased risk | 22 |
knockout mice | 22 |
like receptors | 22 |
induced pulmonary | 22 |
widely used | 22 |
peripheral blood | 22 |
cardiac output | 22 |
tipe overexpression | 22 |
candidate gene | 22 |
ali models | 22 |
ii cells | 22 |
free days | 22 |
lps stimulation | 22 |
chronic obstructive | 22 |
hepatocyte growth | 22 |
human neutrophils | 21 |
expression levels | 21 |
neutrophil infiltration | 21 |
cell surface | 21 |
tidal volumes | 21 |
clinical isolates | 21 |
cytokine signaling | 21 |
obstructive pulmonary | 21 |
genetic association | 21 |
randomized controlled | 21 |
keratinocyte growth | 21 |
ali induced | 21 |
candidate genes | 21 |
saps ii | 21 |
lung function | 21 |
based therapies | 21 |
surfactant protein | 20 |
blot analysis | 20 |
acquired pneumonia | 20 |
wet dry | 20 |
tumor organoids | 20 |
lung stem | 20 |
wt mice | 20 |
high levels | 20 |
three times | 20 |
old female | 20 |
significant increase | 20 |
way anova | 20 |
arterial pressure | 20 |
fi brosis | 20 |
neutrophil elastase | 20 |
self assessment | 20 |
alveolar spaces | 20 |
significantly decreased | 20 |
rac nitration | 20 |
replacement therapy | 20 |
gene coding | 20 |
bacterial infection | 20 |
lung damage | 20 |
migration inhibitory | 20 |
injury model | 20 |
respiratory diseases | 20 |
ali susceptibility | 20 |
ali mice | 19 |
significantly different | 19 |
umbilical cord | 19 |
barrier regulation | 19 |
determined using | 19 |
increased significantly | 19 |
drug screening | 19 |
plasma levels | 19 |
cardiac index | 19 |
cell cycle | 19 |
net formation | 19 |
western blotting | 19 |
predictive value | 19 |
cell counts | 19 |
several studies | 19 |
sofa score | 19 |
inducible nitric | 19 |
extracellular matrix | 19 |
hospital stay | 19 |
respiratory rate | 19 |
tlr expression | 19 |
escherichia coli | 19 |
mouse lung | 19 |
total protein | 19 |
cardiac function | 19 |
red blood | 19 |
lung compliance | 19 |
current study | 19 |
signalling pathway | 19 |
tissue damage | 19 |
palm expression | 19 |
muscle cells | 19 |
risk factor | 18 |
study period | 18 |
cell membrane | 18 |
associated pneumonia | 18 |
kidney injury | 18 |
host immune | 18 |
enhancing factor | 18 |
monoclonal antibody | 18 |
type mice | 18 |
transcription factors | 18 |
supplementary table | 18 |
patients receiving | 18 |
rat lungs | 18 |
endothelial permeability | 18 |
smoke exposure | 18 |
recombinant human | 18 |
negative bacteria | 18 |
dependent manner | 18 |
capillary barrier | 18 |
pandemic influenza | 18 |
human pulmonary | 18 |
receptor signaling | 18 |
blood flow | 18 |
emergency department | 18 |
mrna expression | 18 |
increased vascular | 18 |
ali cultures | 18 |
regression analysis | 18 |
lung water | 18 |
may play | 18 |
alveolar edema | 18 |
cytokine release | 18 |
breast cancer | 18 |
microvascular endothelial | 18 |
derived exosomes | 18 |
cell entry | 17 |
flow cytometry | 17 |
severe lung | 17 |
human coronavirus | 17 |
basal cells | 17 |
cell culture | 17 |
dead space | 17 |
polymicrobial sepsis | 17 |
rd day | 17 |
stress disorder | 17 |
proinflammatory mediators | 17 |
measured using | 17 |
cecal ligation | 17 |
avian influenza | 17 |
injury date | 17 |
blood vessels | 17 |
weight ratio | 17 |
pressure support | 17 |
acute kidney | 17 |
host defense | 17 |
associated virus | 17 |
ml min | 17 |
considered significant | 17 |
evidence suggests | 17 |
acute renal | 17 |
inflammatory cell | 17 |
therapeutic target | 17 |
therapeutic effects | 17 |
neutrophil apoptosis | 17 |
among covid | 17 |
animal studies | 17 |
cortical actin | 17 |
patients infected | 17 |
drug delivery | 17 |
vascular barrier | 17 |
assessment questions | 17 |
cell therapy | 17 |
barrier disruption | 16 |
elevated levels | 16 |
lung edema | 16 |
pulmonary oedema | 16 |
challenged mice | 16 |
cell line | 16 |
neutrophil recruitment | 16 |
intercellular adhesion | 16 |
animal model | 16 |
prospective study | 16 |
prospective observational | 16 |
medical conditions | 16 |
vascular endothelium | 16 |
pathological changes | 16 |
cytoskeletal rearrangement | 16 |
health care | 16 |
preclinical models | 16 |
study showed | 16 |
partial pressure | 16 |
genetic variation | 16 |
infected mice | 16 |
airway organoids | 16 |
adaptive immune | 16 |
experimental studies | 16 |
mlc phosphorylation | 16 |
high risk | 16 |
organoid culture | 16 |
inflammatory effects | 16 |
syncytial virus | 16 |
metabolic pathways | 16 |
therapeutic targets | 16 |
acute pancreatitis | 16 |
personalized medicine | 16 |
novel therapeutic | 16 |
space fraction | 16 |
splen group | 16 |
fio ratio | 15 |
disease modeling | 15 |
patients received | 15 |
potential therapeutic | 15 |
negatively regulates | 15 |
viral infections | 15 |
total rna | 15 |
phase iii | 15 |
actin cytoskeleton | 15 |
two patients | 15 |
retrospective study | 15 |
human genome | 15 |
bl mice | 15 |
ali group | 15 |
total cell | 15 |
stellate ganglia | 15 |
injury caused | 15 |
pg ml | 15 |
acid group | 15 |
neutrophil extracellular | 15 |
par isoforms | 15 |
extracellular traps | 15 |
airway pressure | 15 |
yousaf ali | 15 |
mechanical stress | 15 |
pulmonary artery | 15 |
smartcare ps | 15 |
recent study | 15 |
lung pathology | 15 |
associated lung | 15 |
tumor cells | 15 |
idiopathic pulmonary | 15 |
respiratory syncytial | 15 |
microvascular permeability | 15 |
ali culture | 15 |
ards may | 15 |
university hospital | 15 |
expression profiling | 15 |
protein concentration | 15 |
pulmonary injury | 15 |
previous study | 15 |
activator inhibitor | 15 |
clinical features | 15 |
acute myocardial | 15 |
cystic fi | 15 |
oxygen delivery | 15 |
therapeutic effect | 15 |
vascular leak | 15 |
hospital discharge | 15 |
pulmonary diseases | 15 |
results indicate | 15 |
amino acids | 15 |
recent years | 15 |
inhalation therapy | 15 |
blood products | 15 |
clinical outcomes | 15 |
analyzed using | 15 |
median age | 14 |
extracorporeal membrane | 14 |
humana press | 14 |
injury via | 14 |
serum levels | 14 |
ec permeability | 14 |
pathways involved | 14 |
like neutrophils | 14 |
early phase | 14 |
acute exacerbation | 14 |
treated rats | 14 |
statistical significance | 14 |
group received | 14 |
human studies | 14 |
science business | 14 |
surgical icu | 14 |
icu length | 14 |
reduced lung | 14 |
east respiratory | 14 |
effi ciency | 14 |
linked immunosorbent | 14 |
severe form | 14 |
therapeutic strategy | 14 |
surface area | 14 |
acute inflammatory | 14 |
another study | 14 |
patients undergoing | 14 |
group box | 14 |
springer science | 14 |
remains unclear | 14 |
promoter region | 14 |
intracranial hypertension | 14 |
membrane oxygenation | 14 |
one patient | 14 |
flox control | 14 |
compared using | 14 |
lung organoid | 14 |
mean arterial | 14 |
fisher scientific | 14 |
pulmonary arterial | 14 |
similar results | 14 |
mobility group | 14 |
lung models | 14 |
also found | 14 |
examination reveals | 14 |
mg dl | 14 |
organ injury | 14 |
influenza infection | 14 |
pulmonary endothelium | 14 |
higher risk | 14 |
cell colony | 14 |
tissue injury | 14 |
conscious rats | 14 |
invasive mechanical | 14 |
middle east | 14 |
oxidized phospholipids | 14 |
mg ml | 14 |
evans blue | 14 |
ms ms | 14 |
business media | 14 |
inflammatory bowel | 14 |
cell type | 14 |
proximal airway | 14 |
immunosorbent assay | 14 |
liquid interface | 14 |
protein level | 14 |
diffuse alveolar | 14 |
adhesion molecules | 14 |
lps ifn | 14 |
cell migration | 14 |
buffered saline | 13 |
rac gtpase | 13 |
pufa ratio | 13 |
transepithelial sodium | 13 |
differential expression | 13 |
national institutes | 13 |
animal care | 13 |
intratracheal administration | 13 |
consecutive patients | 13 |
central role | 13 |
derived mesenchymal | 13 |
lipid emulsions | 13 |
deficient mice | 13 |
alveolar macrophage | 13 |
significantly inhibited | 13 |
mediated gene | 13 |
cleaved caspase | 13 |
pivotal role | 13 |
first days | 13 |
mice compared | 13 |
neutrophil accumulation | 13 |
tyrosine phosphorylation | 13 |
invasive ventilation | 13 |
effi cacy | 13 |
per group | 13 |
tissue factor | 13 |
neutrophil proteome | 13 |
lysis buffer | 13 |
respiratory infections | 13 |
goblet cells | 13 |
associated ali | 13 |
lung cells | 13 |
cell cultures | 13 |
stress fibers | 13 |
group compared | 13 |
induced pluripotent | 13 |
pct levels | 13 |
assay kit | 13 |
significantly elevated | 13 |
normal lung | 13 |
based approaches | 13 |
lg ml | 13 |
clinical data | 13 |
sofa scores | 13 |
rights reserved | 13 |
taken together | 13 |
type diabetes | 13 |
pseudomonas aeruginosa | 13 |
ali patients | 13 |
cell infiltration | 13 |
cytokine levels | 13 |
time pcr | 13 |
colorectal cancer | 13 |
infectious diseases | 13 |
increased expression | 13 |
culture system | 13 |
myocardial injury | 12 |
barrier permeability | 12 |
may lead | 12 |
inflammatory effect | 12 |
proliferated aec | 12 |
shrna group | 12 |
key role | 12 |
cellular infiltration | 12 |
lab work | 12 |
may contribute | 12 |
posttraumatic stress | 12 |
gastric cancer | 12 |
prospective cohort | 12 |
adipose tissue | 12 |
lung weight | 12 |
demographic data | 12 |
tissue samples | 12 |
within days | 12 |
icu admissions | 12 |
mouse lungs | 12 |
higher incidence | 12 |
alkaline phosphatase | 12 |
increased pulmonary | 12 |
surviving sepsis | 12 |
ammatory response | 12 |
santa cruz | 12 |
vascular leakage | 12 |
inflammasome assembly | 12 |
th day | 12 |
kg min | 12 |
care medicine | 12 |
nadph oxidase | 12 |
exogenous surfactant | 12 |
made available | 12 |
antibiotic therapy | 12 |
deubiquitinating enzymes | 12 |
fibrin deposition | 12 |
years old | 12 |
tissue repair | 12 |
endothelial progenitor | 12 |
drug discovery | 12 |
intravenous administration | 12 |
polymerase chain | 12 |
deubiquitinating enzyme | 12 |
inflammatory properties | 12 |
mediated transfer | 12 |
cardiopulmonary bypass | 12 |
percutaneous tracheostomy | 12 |
induced sepsis | 12 |
renal replacement | 12 |
acute physiology | 12 |
shock patients | 12 |
higher levels | 12 |
intraperitoneal injection | 12 |
beneficial effects | 12 |
injured patients | 12 |
lung ischemia | 12 |
diabetes mellitus | 12 |
alveolar dead | 12 |
viral vectors | 12 |
among patients | 12 |
drug development | 12 |
described previously | 12 |
month period | 12 |
tlr gene | 12 |
inspired oxygen | 12 |
clara cells | 12 |
oxygen saturation | 12 |
cell count | 12 |
study demonstrated | 12 |
also confirmed | 12 |
plasma membrane | 12 |
arachidonic acid | 12 |
pulmonary pathology | 12 |
immunohistochemical staining | 12 |
whole blood | 12 |
chain reaction | 12 |
secondary antibody | 12 |
alveolar pneumocytes | 12 |
first step | 12 |
genetic variants | 12 |
head injury | 12 |
hyaline membranes | 12 |
renal function | 12 |
gastric contents | 12 |
organoid cultures | 12 |
considered statistically | 11 |
gene transcription | 11 |
central venous | 11 |
cas technology | 11 |
lung parenchyma | 11 |
controlled trials | 11 |
derived hepcidin | 11 |
ethics committee | 11 |
primary human | 11 |
systemic circulation | 11 |
epithelial type | 11 |
response syndrome | 11 |
death risk | 11 |
cell membranes | 11 |
also known | 11 |
died within | 11 |
clinical course | 11 |
fluid transport | 11 |
vitro model | 11 |
induced inflammatory | 11 |
inflammatory markers | 11 |
cigarette smoke | 11 |
pct level | 11 |
mouse monoclonal | 11 |
ali candidate | 11 |
determine whether | 11 |
reduce mortality | 11 |
glutamyl transferase | 11 |
acute pulmonary | 11 |
early stage | 11 |
protein assay | 11 |
injury score | 11 |
receptor antagonist | 11 |
rac protein | 11 |
using crispr | 11 |
study group | 11 |
electron microscopy | 11 |
club cells | 11 |
human bronchial | 11 |
time course | 11 |
cardiogenic pulmonary | 11 |
coronary artery | 11 |
competing interests | 11 |
studies demonstrated | 11 |
complement activation | 11 |
rabbit anti | 11 |
high doses | 11 |
myristate acetate | 11 |
clinical practice | 11 |
infectious disease | 11 |
bronchial epithelial | 11 |
carbon dioxide | 11 |
cell adhesion | 11 |
disease process | 11 |
bowel disease | 11 |
also showed | 11 |
pulmonary drug | 11 |
tir domain | 11 |
free radicals | 11 |
pulmonary endothelial | 11 |
organ models | 11 |
mm tris | 11 |
adult stem | 11 |
activated receptor | 11 |
inflammatory injury | 11 |
pathogenic virus | 11 |
heat shock | 11 |
uric acid | 11 |
human mesenchymal | 11 |
deletion polymorphism | 11 |
gap formation | 11 |
myeloid cells | 11 |
protective role | 11 |
positive control | 11 |
dna damage | 11 |
mesenchymal stromal | 11 |
acid aspiration | 11 |
phase ii | 11 |
spontaneous breathing | 11 |
gene delivery | 11 |
liver injury | 11 |
day survival | 10 |
rac activation | 10 |
angiotensin converting | 10 |
left ventricular | 10 |
interstitial edema | 10 |
important roles | 10 |
patients without | 10 |
cancer stem | 10 |
first period | 10 |
distal lung | 10 |
enteral nutrition | 10 |
clinical study | 10 |
major role | 10 |
gene variants | 10 |
host cells | 10 |
bacterial infections | 10 |
intratracheal instillation | 10 |
right lung | 10 |
cancer cells | 10 |
induced protein | 10 |
pathogenic viruses | 10 |
ventilator associated | 10 |
significantly attenuated | 10 |
vivo studies | 10 |
expiratory pressure | 10 |
major trauma | 10 |
extracellular vesicles | 10 |
dependent pathway | 10 |
sepsis bundles | 10 |
mrna levels | 10 |
supportive care | 10 |
distal airway | 10 |
lower tidal | 10 |
active ingredients | 10 |
sham operation | 10 |
human bone | 10 |
granule proteins | 10 |
tlr myd | 10 |
meningococcal disease | 10 |
normal rats | 10 |
blood cultures | 10 |
intestinal stem | 10 |
spinal afferents | 10 |
infected patients | 10 |
cancer organoids | 10 |
genes involved | 10 |
virus replication | 10 |
pulmonary stem | 10 |
ali rat | 10 |
infected hae | 10 |
cardiovascular disease | 10 |
human disease | 10 |
adverse effects | 10 |
respiratory disease | 10 |
least one | 10 |
neutrophil activation | 10 |
days mortality | 10 |
final nebulisation | 10 |
significant reduction | 10 |
organoid lines | 10 |
scoring system | 10 |
negative control | 10 |
insertion deletion | 10 |
linolenic acid | 10 |
sodium channel | 10 |
alveolar cells | 10 |
cerebral organoids | 10 |
ast treatment | 10 |
lung endothelium | 10 |
organ dysfunctions | 10 |
impaired afc | 10 |
severe pneumonia | 10 |
lung cell | 10 |
lung regeneration | 10 |
patients developed | 10 |
late phase | 10 |
new onset | 10 |
pathway analysis | 10 |
tlr mrna | 10 |
cardiac arrest | 10 |
molecular weight | 10 |
severe hypoxemia | 10 |
mouse anti | 10 |
distal alveolar | 10 |
control animals | 10 |
basement membrane | 10 |
lung wet | 10 |
tyrosine kinase | 10 |
adenoviral vector | 10 |
hepcidin knockdown | 10 |
pulmonary function | 10 |
alveolar wall | 10 |
severe respiratory | 10 |
significant protection | 10 |
functional indexes | 10 |
multivariate analysis | 10 |
community acquired | 10 |
patients treated | 10 |
intracellular iron | 10 |
lung fluid | 10 |
transforming growth | 10 |
pulmonary epithelial | 10 |
laboratory animals | 10 |
even though | 10 |
myeko mice | 10 |
antiviral responses | 10 |
ventilatory support | 10 |
serum hmgb | 10 |
per day | 10 |
soybean oil | 10 |
enteroendocrine cells | 10 |
patients suffering | 10 |
identifi ed | 10 |
improved survival | 10 |
ttp expression | 10 |
adult lung | 10 |
common cause | 10 |
human intestinal | 10 |
cell suspension | 10 |
hepatic functional | 10 |
square test | 10 |
including ali | 10 |
liquid nitrogen | 10 |
injury acute | 10 |
old male | 10 |
phorbol myristate | 10 |
care patients | 10 |
fluid balance | 10 |
many studies | 10 |
therapeutic interventions | 10 |
solid bar | 10 |
clinically relevant | 10 |
septic mice | 10 |
pulmonary circulation | 10 |
septal thickening | 10 |
rna seq | 10 |
influenza viruses | 9 |
secondary antibodies | 9 |
mm nacl | 9 |
surgical patients | 9 |
regression model | 9 |
syndrome acute | 9 |
previous reports | 9 |
healthy volunteers | 9 |
coa reductase | 9 |
coronavirus infection | 9 |
traditional tidal | 9 |
acute inflammation | 9 |
polyclonal antibody | 9 |
ii scores | 9 |
human alveolar | 9 |
hospital charges | 9 |
day post | 9 |
ciliated cells | 9 |
sars coronavirus | 9 |
nitrate nitrite | 9 |
factor kappa | 9 |
cell populations | 9 |
science foundation | 9 |
culture media | 9 |
underlying mechanisms | 9 |
inflammatory process | 9 |
gram negative | 9 |
higher doses | 9 |
rho kinase | 9 |
ace inhibitors | 9 |
liver ischemia | 9 |
epithelial sodium | 9 |
obese patients | 9 |
arterial oxygen | 9 |
oxygenation index | 9 |
medical patients | 9 |
reactive protein | 9 |
gtpase activity | 9 |
significant correlation | 9 |
relative levels | 9 |
traumatic brain | 9 |
national institute | 9 |
first time | 9 |
trauma system | 9 |
signaling technology | 9 |
extravascular lung | 9 |
medical icu | 9 |
side effects | 9 |
deficient neutrophils | 9 |
blood gases | 9 |
inflammatory disorders | 9 |
expression level | 9 |
attenuates acute | 9 |
mm hg | 9 |
mean apache | 9 |
human umbilical | 9 |
per time | 9 |
lung microvascular | 9 |
catalytic domain | 9 |
differential regulation | 9 |
myeloid cell | 9 |
mice treated | 9 |
rheumatoid arthritis | 9 |
studied patients | 9 |
recent advances | 9 |
cell shape | 9 |
mediated ali | 9 |
therapeutic strategies | 9 |
improves survival | 9 |
grant acknowledgement | 9 |
primary antibodies | 9 |
transduction pathways | 9 |
lung alveolar | 9 |
derived mvs | 9 |
days post | 9 |
chemokine receptors | 9 |
adverse events | 9 |
ascitic fluid | 9 |
protease inhibitor | 9 |
apical side | 9 |
multiple comparisons | 9 |
epithelial damage | 9 |
increased lung | 9 |
use committee | 9 |
epithelial organoids | 9 |
fatty acid | 9 |
four members | 9 |
ali caused | 9 |
cold pbs | 9 |
lung development | 9 |
activated receptors | 9 |
flox flox | 9 |
binding lectin | 9 |
essential role | 9 |
gene polymorphisms | 9 |
horseradish peroxidase | 9 |
hairpin rna | 9 |
developed ards | 9 |
angiotensin system | 9 |
culture conditions | 9 |
standard deviation | 9 |
positive end | 9 |
six patients | 9 |
single nucleotide | 9 |
lgr stem | 9 |
alveolar walls | 9 |
genes coding | 9 |
teaching hospital | 9 |
cardiogenic shock | 9 |
tyrosine nitration | 9 |
controlled clinical | 9 |
light microscope | 9 |
respiratory system | 9 |
positive association | 9 |
transduction pathway | 9 |
hypoxemic respiratory | 9 |
factor gene | 9 |
increased permeability | 9 |
large number | 9 |
roc curve | 9 |
san diego | 9 |
lung index | 9 |
overzealous host | 9 |
induced increase | 9 |
airway inflammation | 9 |
biological processes | 9 |
predicted mortality | 9 |
surface expression | 9 |
mv duration | 9 |
plasma extravasation | 9 |
proteins involved | 9 |
major cause | 9 |
phosphate receptor | 9 |
transient receptor | 9 |
sized blood | 9 |
severely ill | 9 |
cell function | 9 |
vascular smooth | 9 |
terminal kinase | 9 |
isolated rat | 9 |
epidermal growth | 9 |
zika virus | 9 |
interstitial lung | 9 |
mice lacking | 9 |
long term | 9 |
traumatic stress | 9 |
natural science | 9 |
normal human | 9 |
beneficial effect | 9 |
met signaling | 9 |
significantly improved | 9 |
focal adhesion | 9 |
lung fibrosis | 9 |
lower respiratory | 9 |
intracranial pressure | 8 |
sars patients | 8 |
statistical analyses | 8 |
severe ards | 8 |
tight junction | 8 |
different cell | 8 |
also reduced | 8 |
lps induces | 8 |
knockdown mice | 8 |
brain dysfunction | 8 |
time rt | 8 |
binding proteins | 8 |
organ damage | 8 |
also significantly | 8 |
graphpad prism | 8 |
core degs | 8 |
independent risk | 8 |
cause ali | 8 |
inflammasome activity | 8 |
edema associated | 8 |
i cells | 8 |
activator protein | 8 |
inflammatory mediator | 8 |
mice per | 8 |
lpsinduced ali | 8 |
oxygen partial | 8 |
ii epithelial | 8 |
confocal microscopy | 8 |
hiv aids | 8 |
also used | 8 |
patients required | 8 |
null mice | 8 |
cell survival | 8 |
rho gtpases | 8 |
sepsis campaign | 8 |
molecular mechanism | 8 |
macrophage colony | 8 |
alveolar oedema | 8 |
factor alpha | 8 |
diurnal changes | 8 |
kappab activation | 8 |
vital signs | 8 |
alo monolayers | 8 |
total number | 8 |
small intestine | 8 |
acute brain | 8 |
differential diagnosis | 8 |
wistar rats | 8 |
investigate whether | 8 |
attractive target | 8 |
nitrated rac | 8 |
circulating neutrophils | 8 |
cell damage | 8 |
granted medrxiv | 8 |
chemoattractant protein | 8 |
normal saline | 8 |
airspace edema | 8 |
lps exposure | 8 |
international cohort | 8 |
enter cells | 8 |
human respiratory | 8 |
five patients | 8 |
lung protective | 8 |
higher expression | 8 |
rna viruses | 8 |
ace expression | 8 |
wet weight | 8 |
work reveals | 8 |
icu discharge | 8 |
defense mechanisms | 8 |
ventilator settings | 8 |
induced ec | 8 |
author funder | 8 |
poor outcome | 8 |
neutralizing antibody | 8 |
study suggests | 8 |
human colon | 8 |
marrow mscs | 8 |
data indicate | 8 |
culture medium | 8 |
murine models | 8 |
gene ontology | 8 |
day group | 8 |
thrombin receptor | 8 |
several polymorphisms | 8 |
acute phase | 8 |
receptor agonists | 8 |
significant higher | 8 |
adrenergic agonists | 8 |
eicosapentaenoic acid | 8 |
liver organoids | 8 |
ill patient | 8 |
age years | 8 |
pathway using | 8 |
conditioned media | 8 |
respiratory infection | 8 |
blocking buffer | 8 |
vascular hyperpermeability | 8 |
ventilation strategy | 8 |
differential metabolites | 8 |
disease severity | 8 |
low levels | 8 |
may help | 8 |
cytokine il | 8 |
clinical investigations | 8 |
intratracheal injection | 8 |
lung macrophages | 8 |
complex formation | 8 |
expiratory flow | 8 |
target genes | 8 |
wash buffer | 8 |
injury mice | 8 |
kidney organoids | 8 |
brain injury | 8 |
mortality prediction | 8 |
extracellular pbef | 8 |
reduced expression | 8 |
hydrogen peroxide | 8 |
granulocyte colony | 8 |
serum tnf | 8 |
requiring mechanical | 8 |
cultured cells | 8 |
protein substrates | 8 |
neutrophil sequestration | 8 |
vascular integrity | 8 |
international license | 8 |
analysis revealed | 8 |
viral infectivity | 8 |
inflammasome formation | 8 |
neutrophil migration | 8 |
healthy controls | 8 |
endosome pathway | 8 |
tipe treatment | 8 |
tlr trif | 8 |
showed significant | 8 |
findings suggest | 8 |
palm gene | 8 |
mediated inflammation | 8 |
injury group | 8 |
also shown | 8 |
short hairpin | 8 |
ljf groups | 8 |
quantified using | 8 |
lower mortality | 8 |
low tidal | 8 |
two studies | 8 |
ttp overexpression | 8 |
post hoc | 8 |
cell carcinoma | 8 |
pulmonary embolism | 8 |
four patients | 8 |
magnesium sulphate | 8 |
inclusion criteria | 8 |
lps treatment | 8 |
orally inhaled | 8 |
animal experiments | 8 |
proteomic analysis | 8 |
mass spectrometry | 8 |
clinical outcome | 8 |
mice infected | 8 |
various cell | 8 |
nutrition support | 8 |
live rats | 8 |
nuclear extracts | 8 |
tumor suppressor | 8 |
bca protein | 8 |
viral rna | 8 |
cells per | 8 |
serum amyloid | 8 |
linkage disequilibrium | 8 |
might also | 8 |
activating factor | 8 |
cell niche | 8 |
randomly assigned | 8 |
confocal images | 8 |
viral replication | 8 |
clinical evidence | 8 |
angiotensin i | 8 |
matrix metalloproteinases | 8 |
receptor potential | 8 |
treat covid | 8 |
mitochondrial transfer | 8 |
signaling cascades | 8 |
related genes | 8 |
induced increases | 8 |
air embolism | 8 |
natural killer | 8 |
human neutrophil | 8 |
nervous system | 8 |
therapeutic efficacy | 8 |
patient population | 8 |
injury following | 8 |
vitro studies | 8 |
canine model | 8 |
year period | 8 |
study indicates | 8 |
hospital length | 8 |
acid injection | 8 |
eff ective | 8 |
experimental design | 8 |
regulatory factor | 8 |
molecular targets | 8 |
mediated lung | 8 |
specific ttp | 8 |
colon cancer | 8 |
may affect | 8 |
like cells | 8 |
patients presented | 8 |
pleural effusion | 8 |
transmembrane conductance | 8 |
based nams | 8 |
sepsis induced | 8 |
human subjects | 8 |
novel biomarker | 8 |
angiotensin receptor | 8 |
barrier protection | 8 |
less likely | 8 |
induced barrier | 8 |
ovarian cancer | 8 |
dysfunction syndrome | 8 |
vegf levels | 8 |
protein concentrations | 8 |
via inhibiting | 8 |
pattern recognition | 8 |
rabbit polyclonal | 8 |
normal range | 8 |
expression omnibus | 8 |
studies showed | 8 |
based lipid | 8 |
high power | 8 |
elderly patients | 8 |
serum albumin | 8 |
vitro expansion | 8 |
induced tlr | 8 |
bronchioalveolar stem | 8 |
early endosome | 8 |
plasma concentration | 8 |
mice lungs | 8 |
severe ali | 8 |
successfully used | 8 |
give rise | 8 |
antioxidant supplementation | 8 |
ion transport | 8 |
genetic material | 8 |
genome editing | 8 |
perivascular edema | 8 |
per year | 8 |
mg day | 8 |
genetic factors | 8 |
inhibition group | 8 |
cord blood | 8 |
polyunsaturated fatty | 8 |
treat ali | 8 |
human pluripotent | 8 |
significant decrease | 8 |
studies suggest | 8 |
tlr inhibition | 8 |
organoid models | 8 |
first day | 8 |
colony enhancing | 7 |
derived factor | 7 |
also increased | 7 |
severe septic | 7 |
single cells | 7 |
descriptive study | 7 |
actin ring | 7 |
recipient mice | 7 |
gene family | 7 |
bovine serum | 7 |
pbef neutralizing | 7 |
brush border | 7 |
apical surface | 7 |
comorbid medical | 7 |
infarct size | 7 |
findings indicate | 7 |
alveolar septal | 7 |
lung injuries | 7 |
may infl | 7 |
lactate requests | 7 |
icu ventilators | 7 |
cells derived | 7 |
therapeutic options | 7 |
genetic predisposition | 7 |
ali vs | 7 |
lactate levels | 7 |
single cell | 7 |
conditioned medium | 7 |
kinase gene | 7 |
respiratory muscles | 7 |
septic animals | 7 |
tlr ligands | 7 |
sample size | 7 |
leading cause | 7 |
also demonstrated | 7 |
significant increases | 7 |
adrenergic receptor | 7 |
thromboplastin time | 7 |
canine models | 7 |
significantly associated | 7 |
base excess | 7 |
base pairs | 7 |
stromal cell | 7 |
mice showed | 7 |
cell differentiation | 7 |
isolated lungs | 7 |
non invasive | 7 |
organoids culture | 7 |
transmission electron | 7 |
survival rates | 7 |
curcuma longa | 7 |
epidemiologic studies | 7 |
preclinical studies | 7 |
i interferon | 7 |
alveolar capillary | 7 |
relative expression | 7 |
physiology score | 7 |
induced apoptosis | 7 |
lung model | 7 |
gas analysis | 7 |
anticoagulant effects | 7 |
ttp levels | 7 |
inflammatory processes | 7 |
pilot study | 7 |
life technologies | 7 |
exclusion criteria | 7 |
respiratory insufficiency | 7 |
intestinal epithelial | 7 |
host inflammation | 7 |
final manuscript | 7 |
underlying ali | 7 |
rna interference | 7 |
endogenous stem | 7 |
highly expressed | 7 |
tolllike receptor | 7 |
actin filaments | 7 |
niv mode | 7 |
fat embolism | 7 |
hepatocellular injury | 7 |
factor viia | 7 |
nlrp pathway | 7 |
organoids using | 7 |
histological examination | 7 |
ali remains | 7 |
surfactant proteins | 7 |
pmn nad | 7 |
per well | 7 |
required mechanical | 7 |
still remains | 7 |
simplified acute | 7 |
pulsatility index | 7 |
experimental sepsis | 7 |
neutrophil counts | 7 |
human macrophages | 7 |
nlrp asc | 7 |
fibroproliferative phase | 7 |
regenerative medicine | 7 |
major causes | 7 |
blue dye | 7 |
viral entry | 7 |
nlrp activation | 7 |
poor correlation | 7 |
pulmonary organ | 7 |
future studies | 7 |
may provide | 7 |
experimental study | 7 |
may occur | 7 |
chronic renal | 7 |
much less | 7 |
positive bacteria | 7 |
chemokine receptor | 7 |
general icu | 7 |
sham group | 7 |
relevant outcomes | 7 |
may serve | 7 |
markedly attenuated | 7 |
inflammatory reactions | 7 |
chest pain | 7 |
medical records | 7 |
including il | 7 |
general wards | 7 |
cells within | 7 |
promoter polymorphism | 7 |
lung infl | 7 |
prone positioning | 7 |
partial thromboplastin | 7 |
copyright holder | 7 |
multicenter study | 7 |
immunofluorescence staining | 7 |
graphpad software | 7 |
results show | 7 |
antiviral response | 7 |
admission diagnosis | 7 |
induced septic | 7 |
hospitalized patients | 7 |
intravascular coagulation | 7 |
macrophage activation | 7 |
least three | 7 |
stimulated afc | 7 |
receptor blockers | 7 |
rescue therapies | 7 |
differentiated human | 7 |
ards ali | 7 |
antimicrobial peptides | 7 |
serine protease | 7 |
novel therapies | 7 |
poorly understood | 7 |
blood barrier | 7 |
randomly divided | 7 |
neutrophilic lung | 7 |
specific protease | 7 |
following ali | 7 |
drug administration | 7 |
study also | 7 |
clinical manifestations | 7 |
cov infection | 7 |
low dose | 7 |
adenosine monophosphate | 7 |
genetic information | 7 |
repair process | 7 |
four hours | 7 |
small airway | 7 |
center study | 7 |
primary outcome | 7 |
goat anti | 7 |
nucleic acid | 7 |
associated acute | 7 |
transgene expression | 7 |
study design | 7 |
late endosome | 7 |
inhibitory effects | 7 |
significant association | 7 |
vegfr mrna | 7 |
target range | 7 |
lung infections | 7 |
rapid response | 7 |
type cells | 7 |
pancreatic ductal | 7 |
injury may | 7 |
effi cient | 7 |
basic science | 7 |
recent evidence | 7 |
activated neutrophils | 7 |
confidence interval | 7 |
small intestinal | 7 |
bal protein | 7 |
well known | 7 |
pulmonary infiltrates | 7 |
failure due | 7 |
enhanced cleaning | 7 |
related quality | 7 |
genes related | 7 |
data showed | 7 |
splen groups | 7 |
brain organoids | 7 |
surfactant therapy | 7 |
kidney disease | 7 |
myocardial ischemia | 7 |
iron content | 7 |
human tissues | 7 |
will help | 7 |
independently associated | 7 |
pancreatic cancer | 7 |
preclinical animal | 7 |
mortality benefit | 7 |
ali method | 7 |
two different | 7 |
term expansion | 7 |
potential targets | 7 |
stress doses | 7 |
routinely used | 7 |
promising results | 7 |
data collection | 7 |
decreased expression | 7 |
conductance regulator | 7 |
wet lung | 7 |
onset severe | 7 |
potential role | 7 |
liver transplantation | 7 |
surfactant system | 7 |
flow rate | 7 |
group treated | 7 |
postoperative period | 7 |
fluid reabsorption | 7 |
study shows | 7 |
associated proteins | 7 |
markedly elevated | 7 |
inflammatory disease | 7 |
artery bypass | 7 |
endosomal pathway | 7 |
induced neutrophil | 7 |
pulmonary infection | 7 |
zfp flox | 7 |
tumour necrosis | 7 |
blood neutrophils | 7 |
blood vessel | 7 |
studies reported | 7 |
pulmonary expression | 7 |
lung epithelium | 7 |
total body | 7 |
clinical setting | 7 |
eff ects | 7 |
mucociliary clearance | 7 |
induce ali | 7 |
following lps | 7 |
post ali | 7 |
enteral feeding | 7 |
myeloid differentiation | 7 |
nucleotide polymorphism | 7 |
seq results | 7 |
permeability pulmonary | 7 |
induced endothelial | 7 |
receptor expression | 7 |
epithelial fluid | 7 |
new therapeutic | 6 |
severe asthma | 6 |
fluid resuscitation | 6 |
cultured human | 6 |
improved outcomes | 6 |
last years | 6 |
enzyme gene | 6 |
rectal cancer | 6 |
adherens junctions | 6 |
sphingosine kinase | 6 |
ctrl group | 6 |
many patients | 6 |
treatment option | 6 |
th ese | 6 |
controlled study | 6 |
ali induction | 6 |
ubiquitin chains | 6 |
help identify | 6 |
therapeutic agent | 6 |
association study | 6 |
drug response | 6 |
lps ad | 6 |
per high | 6 |
generate tumors | 6 |
significantly downregulated | 6 |
human ipsc | 6 |
attenuates endotoxin | 6 |
aud patients | 6 |
antioxidant therapy | 6 |
box protein | 6 |
common genetic | 6 |
ifn signaling | 6 |
improved cardiac | 6 |
marrow mesenchymal | 6 |
ovariectomized rats | 6 |
respiratory mechanics | 6 |
fl uid | 6 |
endotoxic shock | 6 |
european descent | 6 |
hepatocellular carcinoma | 6 |
per patient | 6 |
fl fl | 6 |
two types | 6 |
sustained viral | 6 |
also reported | 6 |
cutting edge | 6 |
closely related | 6 |
histological changes | 6 |
kinase activation | 6 |
neutrophilic infiltration | 6 |
crucial role | 6 |
genetic recombination | 6 |
combination therapy | 6 |
jaam dic | 6 |
tnf therapy | 6 |
ali risk | 6 |
serum lactate | 6 |
included patients | 6 |
authors read | 6 |
profi le | 6 |
network pharmacology | 6 |
lipid emulsion | 6 |
mechanisms involved | 6 |
receiving mechanical | 6 |
basic research | 6 |
corresponding ali | 6 |
vascular injury | 6 |
liver disease | 6 |
hepcidin expression | 6 |
mice received | 6 |
cells may | 6 |
interferon signaling | 6 |
baseline levels | 6 |
modified score | 6 |
regulated protein | 6 |
protects mice | 6 |
treated patients | 6 |
first line | 6 |
trial coordination | 6 |
reduced mortality | 6 |
ali may | 6 |
inspiratory muscle | 6 |
respiratory dysfunction | 6 |
exosomes derived | 6 |
fi brinogen | 6 |
tissue sections | 6 |
gov identifier | 6 |
decreased mortality | 6 |
inflammasome pathway | 6 |
ly i | 6 |
retinoic acid | 6 |
cancer cell | 6 |
antimicrobial therapy | 6 |
mediates lung | 6 |
extracellular signal | 6 |
tlr upregulation | 6 |
human monocytes | 6 |
clinical review | 6 |
traf traf | 6 |
rats treated | 6 |
small interfering | 6 |
tumor microenvironment | 6 |
retrospective analysis | 6 |
prism software | 6 |
adherens junction | 6 |
cell motility | 6 |
normal organoids | 6 |
recognition receptors | 6 |
challenged flox | 6 |
pulmonary dead | 6 |
patients requiring | 6 |
response team | 6 |
interferon regulatory | 6 |
single lgr | 6 |
signal transducer | 6 |
jnk activation | 6 |
su treated | 6 |
urine output | 6 |
tight junctions | 6 |
mechanisms underlying | 6 |
personalized treatment | 6 |
lps groups | 6 |
lung repair | 6 |
enrichment analysis | 6 |
negative effects | 6 |
severe pulmonary | 6 |
rodent model | 6 |
carotid artery | 6 |
prospectively collected | 6 |
better understanding | 6 |
fold change | 6 |
palm knockdown | 6 |
low doses | 6 |
quantitative analysis | 6 |
target cells | 6 |
heparin dosage | 6 |
multivariate logistic | 6 |
ventilation strategies | 6 |
pufa administration | 6 |
embryonic stem | 6 |
positive findings | 6 |
receiver operating | 6 |
organoid biobank | 6 |
case report | 6 |
chest radiograph | 6 |
master mix | 6 |
successfully established | 6 |
positive airway | 6 |
transcriptional regulation | 6 |
mast cells | 6 |
akt pathway | 6 |
interacting protein | 6 |
chronic lung | 6 |
epithelial permeability | 6 |
mechanism underlying | 6 |
ammatory cytokines | 6 |
early stages | 6 |
purified using | 6 |
family members | 6 |
induced changes | 6 |
activated partial | 6 |
human small | 6 |
bronchopulmonary dysplasia | 6 |
disease models | 6 |
cell permeability | 6 |
early identification | 6 |
treated group | 6 |
iron metabolism | 6 |
ali rats | 6 |
gel electrophoresis | 6 |
also involved | 6 |
alveolar septum | 6 |
inflammatory stimuli | 6 |
identifier nct | 6 |
aav vector | 6 |
clinical isolate | 6 |
human ali | 6 |
may cause | 6 |
score ii | 6 |
improved oxygenation | 6 |
pneumococcal pneumonia | 6 |
clinical problem | 6 |
aec cell | 6 |
vivo net | 6 |
congestive heart | 6 |
chronic health | 6 |
gene approach | 6 |
odds ratio | 6 |
capillary leak | 6 |
reduced levels | 6 |
tertiary referral | 6 |
kg body | 6 |
dry ratio | 6 |
primary antibody | 6 |
pbef expression | 6 |
neutralizing antibodies | 6 |
functional repair | 6 |
interim analysis | 6 |
lung specimens | 6 |
mylk gene | 6 |
protein content | 6 |
humanized anti | 6 |
cell receptor | 6 |
alveolar injury | 6 |
cohort studies | 6 |
dark cycle | 6 |
established ards | 6 |
notch signaling | 6 |
using western | 6 |
therapeutic intervention | 6 |
cftr function | 6 |
study aimed | 6 |
cre zfp | 6 |
tissue plasminogen | 6 |
conjugated secondary | 6 |
sepsis guideline | 6 |
protein kinases | 6 |
influenza group | 6 |
containing adaptor | 6 |
promising potential | 6 |
zn levels | 6 |
animal study | 6 |
focal adhesions | 6 |
immune cell | 6 |
clinically significant | 6 |
european consensus | 6 |
endoplasmic reticulum | 6 |
ali mouse | 6 |
viral load | 6 |
clinical symptoms | 6 |
care facilities | 6 |
bacterial pneumonia | 6 |
ii alveolar | 6 |
severe community | 6 |
pulmonary inflammatory | 6 |
environmental factors | 6 |
mediated endothelial | 6 |
neutrophils purified | 6 |
attenuates lipopolysaccharide | 6 |
chest radiography | 6 |
related ali | 6 |
control groups | 6 |
unpaired two | 6 |
patients often | 6 |
normally distributed | 6 |
proliferated cells | 6 |
actin stress | 6 |
actin polymerization | 6 |
poor prognosis | 6 |
helicobacter pylori | 6 |
stellate injection | 6 |
publicly available | 6 |
gold standard | 6 |
derived intestinal | 6 |
two distinct | 6 |
higher rate | 6 |
polymorphonuclear neutrophils | 6 |
high mobility | 6 |
care doi | 6 |
organoids model | 6 |
lactic acidosis | 6 |
ace levels | 6 |
frequency oscillatory | 6 |
soluble intercellular | 6 |
patients underwent | 6 |
translational research | 6 |
associated protein | 6 |
consensus conference | 6 |
patient ventilator | 6 |
important mechanism | 6 |
murine lung | 6 |
tipe lps | 6 |
potential novel | 6 |
cerebral compression | 6 |
multiorgan failure | 6 |
animal research | 6 |
higher peep | 6 |
cytometry analysis | 6 |
urban areas | 6 |
parenteral nutrition | 6 |
inhaled drugs | 6 |
shorter duration | 6 |
blood lactate | 6 |
regulating vascular | 6 |
laboratory animal | 6 |
organic acids | 6 |
chi square | 6 |
effector domain | 6 |
washed twice | 6 |
ali via | 6 |
extracellular atp | 6 |
ethnic groups | 6 |
patients using | 6 |
ii receptor | 6 |
oscillatory ventilation | 6 |
experimental data | 6 |
hepcidin gene | 6 |
total cells | 6 |
serious adverse | 6 |
spike protein | 6 |
atp release | 6 |
alveolar hemorrhage | 6 |
bal fluids | 6 |
human endothelial | 6 |
japanese encephalitis | 6 |
play important | 6 |
matched normal | 6 |
molecular subtypes | 6 |
mononuclear cells | 6 |
general hospital | 6 |
twice daily | 6 |
septic aki | 6 |
may reduce | 6 |
significant improvement | 6 |
mouse models | 6 |
whitney test | 6 |
studies examining | 6 |
complement system | 6 |
cardiac surgical | 6 |
respiratory support | 6 |
intravenous injection | 6 |
dependent cytoskeletal | 6 |
paracellular gap | 6 |
rna sequencing | 6 |
van der | 6 |
dub family | 6 |
gastric organoids | 6 |
mean values | 6 |
mice exhibit | 6 |
life support | 6 |
power field | 6 |
ventilator days | 6 |
cumulative fb | 6 |
cell lung | 6 |
phosphorylated mlc | 6 |
attenuated lps | 6 |
serum creatinine | 6 |
inflammatory gene | 6 |
reverse transcription | 6 |
enhanced expression | 6 |
inhibitory effect | 6 |
organ failures | 6 |
fully understood | 6 |
lung homogenate | 6 |
prone position | 6 |
peroxisome proliferator | 6 |
ubiquitinated protein | 6 |
perivascular inflammation | 6 |
national natural | 6 |
interfacility transfers | 6 |
blood transfusion | 6 |
colon organoids | 6 |
curcumin reduced | 6 |
buffered formalin | 6 |
related mortality | 6 |
genetically engineered | 6 |
lung sections | 6 |
airway cells | 6 |
circadian oscillations | 6 |
transgenic mice | 6 |
cell activation | 6 |
staphylococcus aureus | 6 |
patients may | 6 |
provide evidence | 6 |
lung liquid | 6 |
research tool | 6 |
vagus nerve | 6 |
inos mrna | 6 |
tlr activation | 6 |
three patients | 6 |
sequencing data | 6 |
studies using | 6 |
treatment group | 6 |
randomised controlled | 6 |
cells overexpressing | 6 |
intestinal ischemia | 5 |
patient outcome | 5 |
related molecules | 5 |
pmn infiltration | 5 |
lactate level | 5 |
sample sizes | 5 |
observer reliability | 5 |
overt dic | 5 |
growing body | 5 |
receptor family | 5 |
cause mortality | 5 |
modifi ed | 5 |
attenuated lung | 5 |
cell gap | 5 |
novel role | 5 |
clinical conditions | 5 |
patients older | 5 |
commercially available | 5 |
sepsis syndrome | 5 |
statin therapy | 5 |
active lung | 5 |
proteasomal degradation | 5 |
hepcidin level | 5 |
rac inhibition | 5 |
weight loss | 5 |
body mass | 5 |
muramyl dipeptide | 5 |
fluid therapy | 5 |
serine proteases | 5 |
might contribute | 5 |
soft tissue | 5 |
flap region | 5 |
also examined | 5 |
significantly upregulated | 5 |
erythema nodosum | 5 |
nosocomial infection | 5 |
ad libitum | 5 |
epithelial progenitor | 5 |
der gesundheitsbezogenen | 5 |
ct scan | 5 |
patient demographics | 5 |
oid testing | 5 |
tissue homogenates | 5 |
nr ab | 5 |
end expiratory | 5 |
polymorphonuclear leukocytes | 5 |
cancer patients | 5 |
dex group | 5 |
septic group | 5 |
previously reported | 5 |
patients died | 5 |
abdominal incision | 5 |
values less | 5 |
epithelial monolayer | 5 |
negative selection | 5 |
received mechanical | 5 |
normal level | 5 |
ameliorates lipopolysaccharide | 5 |
experimental acute | 5 |
detrimental role | 5 |
markedly reduced | 5 |
high tidal | 5 |
consecutive days | 5 |
early postoperative | 5 |
specific pathogen | 5 |
berlin definition | 5 |
stress fiber | 5 |
epithelial stem | 5 |
disease processes | 5 |
immunocompromised mice | 5 |
surgical wards | 5 |
enzyme insertion | 5 |
alveolar flooding | 5 |
shock may | 5 |
statistical difference | 5 |
induced airway | 5 |
experimental models | 5 |
may result | 5 |
mouse neutrophils | 5 |
irradiated ttp | 5 |
positive staining | 5 |
initial treatment | 5 |
significant neutrophil | 5 |
mortality reduction | 5 |
lymphocyte counts | 5 |
lps injection | 5 |
negative predictive | 5 |
aa ratios | 5 |
cytoskeletal changes | 5 |
socs expression | 5 |
hepatic function | 5 |
dry ratios | 5 |
human gastric | 5 |
mpo granule | 5 |
translational modification | 5 |
may allow | 5 |
forming capacity | 5 |
methods section | 5 |
see table | 5 |
cationic lipid | 5 |
correlation coefficient | 5 |
fluid responsiveness | 5 |
cell isolation | 5 |
alveolar cell | 5 |
protein family | 5 |
studies found | 5 |
lps instillation | 5 |
allergic airway | 5 |
ammatory cytokine | 5 |
vegf gene | 5 |
ang ii | 5 |
collected data | 5 |
derived growth | 5 |
therapeutic regimen | 5 |
inflammatory reaction | 5 |
using real | 5 |
disseminated intravascular | 5 |
oid deposition | 5 |
neutrophil chemoattractants | 5 |
mixed medical | 5 |
i ifn | 5 |
enhancing effect | 5 |
polyvinylidene difluoride | 5 |
autoimmune disease | 5 |
older age | 5 |
cognitive dysfunction | 5 |
strongly associated | 5 |
transcriptional changes | 5 |
several clinical | 5 |
procoagulant molecules | 5 |
protein stability | 5 |
volume ventilation | 5 |
representative confocal | 5 |
active compounds | 5 |
lung transplantation | 5 |
wide association | 5 |
blood sample | 5 |
multiple testing | 5 |
organoid biobanks | 5 |
multiple organs | 5 |
specific forms | 5 |
intratracheally administered | 5 |
multiple transfusions | 5 |
murine macrophages | 5 |
cell numbers | 5 |
total hospital | 5 |
weaning criteria | 5 |
pathogenic viral | 5 |
left lung | 5 |
enrolled patients | 5 |
medical center | 5 |
ct scans | 5 |
anova followed | 5 |
ali initiation | 5 |
isolated perfused | 5 |
clinical management | 5 |
injury models | 5 |
rad laboratories | 5 |
phosphatebuffered saline | 5 |
normal control | 5 |
groups increased | 5 |
capillary bed | 5 |
non parametric | 5 |
human liver | 5 |
derived monolayers | 5 |
neutrophil exudation | 5 |
enteral formula | 5 |
med doi | 5 |
asc caspase | 5 |
meoh meoh | 5 |
mitochondrial function | 5 |
including immune | 5 |
perfused rat | 5 |
bipap vision | 5 |
experimental model | 5 |
droplets particles | 5 |
old patients | 5 |
functional outcome | 5 |
major histocompatibility | 5 |
studies will | 5 |
related diseases | 5 |
cord mesenchymal | 5 |
inflammatory activity | 5 |
iii clinical | 5 |
various types | 5 |
washed three | 5 |
syndrome network | 5 |
including lung | 5 |
treatment improves | 5 |
neutrophil function | 5 |
neutrophil numbers | 5 |
direct causes | 5 |
endothelial cadherin | 5 |
cells also | 5 |
influenza pandemic | 5 |
tunel staining | 5 |
cases per | 5 |
monocyte chemoattractant | 5 |
cell suspensions | 5 |
cardiovascular system | 5 |
one patients | 5 |
may exert | 5 |
syndrome pulmonary | 5 |
receptor signalling | 5 |
clara cell | 5 |
burn patients | 5 |
reduced plasma | 5 |
study examining | 5 |
glasgow coma | 5 |
significant changes | 5 |
prosthetic valve | 5 |
injury patients | 5 |
coma scale | 5 |
log rank | 5 |
transport across | 5 |
androgen receptor | 5 |
fi brinolysis | 5 |
health evaluation | 5 |
bacterial clearance | 5 |
transendothelial migration | 5 |
cytokines including | 5 |
blood lymphocytes | 5 |
fluid challenge | 5 |
future research | 5 |
clinical utility | 5 |
terminal hydrolases | 5 |
intratracheal lps | 5 |
melatonin treatment | 5 |
lung biopsies | 5 |
seven patients | 5 |
original magnification | 5 |
pancreatic organoids | 5 |
free access | 5 |
mediated knock | 5 |
cpa patients | 5 |
antigen receptor | 5 |
volume mechanical | 5 |
cytokine expression | 5 |
comparison test | 5 |
ace gene | 5 |
representative photomicrographs | 5 |
cftr channel | 5 |
ventricular function | 5 |
susceptibility gene | 5 |
cellular barrier | 5 |
adaptor inducing | 5 |
underlying disease | 5 |
adaptive immunity | 5 |
quality control | 5 |
damage induced | 5 |
systemic diseases | 5 |
derived human | 5 |
type neutrophils | 5 |
clinical significance | 5 |
imaging system | 5 |
rifle criteria | 5 |
dubs might | 5 |
rectal organoids | 5 |
negative regulation | 5 |
intensivmedizinischen behandlung | 5 |
aids patients | 5 |
dha aa | 5 |
tract infection | 5 |
dexamethasone group | 5 |
main active | 5 |
time quantitative | 5 |
may improve | 5 |
one hour | 5 |
lung mpo | 5 |
target cell | 5 |
lung section | 5 |
blood cell | 5 |
cell lysis | 5 |
cell sorting | 5 |
ards secondary | 5 |
proteome changes | 5 |
phagocytic cells | 5 |
severe inflammation | 5 |
competence assessment | 5 |
assess whether | 5 |
many types | 5 |
post lps | 5 |
randomized trial | 5 |
signifi cantly | 5 |
developing ards | 5 |
mortality risk | 5 |
conjugating enzymes | 5 |
lpschallenged ttp | 5 |
oxidative burst | 5 |
rank test | 5 |
expression patterns | 5 |
cell organoids | 5 |
well plates | 5 |
assessed using | 5 |
study provides | 5 |
injury role | 5 |
membrane formation | 5 |
care services | 5 |
induced cell | 5 |
hemodynamic changes | 5 |
cerebral hyperperfusion | 5 |
last decade | 5 |
mice exhibited | 5 |
deceased covid | 5 |
drug sensitivity | 5 |
well tolerated | 5 |
common causes | 5 |
semiquantitative histopathological | 5 |
clinical application | 5 |
possible molecular | 5 |
world health | 5 |
large surface | 5 |
first interim | 5 |
large numbers | 5 |
novel mechanism | 5 |
histocompatibility complex | 5 |
enhanced chemiluminescence | 5 |
trend towards | 5 |
histopathological scoring | 5 |
inhibiting nlrp | 5 |
death effector | 5 |
circuit life | 5 |
failure assessment | 5 |
accession number | 5 |
prognostic factors | 5 |
among groups | 5 |
hospital admission | 5 |
cells following | 5 |
light cycle | 5 |
following admission | 5 |
novel therapeutics | 5 |
elisa assay | 5 |
excessive inflammatory | 5 |
blotting analysis | 5 |
ii modified | 5 |
factors associated | 5 |
rat liver | 5 |
histological subtypes | 5 |
edema resolution | 5 |
shock group | 5 |
mortality data | 5 |
restore lung | 5 |
valve replacement | 5 |
clinical implications | 5 |
hematopoietic stem | 5 |
intensive insulin | 5 |
often associated | 5 |
trif protein | 5 |
demographic characteristics | 5 |
shock admitted | 5 |
airway components | 5 |
specific inhibitor | 5 |
rabbit igg | 5 |
antigen retrieval | 5 |
muscle mlck | 5 |
arterial hypertension | 5 |
one year | 5 |
patients needed | 5 |
endogenous surfactant | 5 |
pneumoniae infection | 5 |
apoptotic cells | 5 |
new insights | 5 |
one study | 5 |
total volume | 5 |
retrospective review | 5 |
saline group | 5 |
multiple genes | 5 |
superoxide dismutase | 5 |
elisa kits | 5 |
authors reported | 5 |
autologous transplantation | 5 |
public health | 5 |
extracellular dna | 5 |
urinary tract | 5 |
adenoviral gene | 5 |
stroke volume | 5 |
plasma vegf | 5 |
every patient | 5 |
male wistar | 5 |
respiratory epithelium | 5 |
blood volume | 5 |
muc ac | 5 |
alo lines | 5 |
fi brin | 5 |
decreased lung | 5 |
way analysis | 5 |
binding sites | 5 |
inducing interferon | 5 |
high vascular | 5 |
pufa supply | 5 |
previous report | 5 |
peer review | 5 |
medical university | 5 |
like protein | 5 |
sepsis group | 5 |
rich edema | 5 |
capsid proteins | 5 |
new treatment | 5 |
indirect injury | 5 |
independent predictor | 5 |
expression analysis | 5 |
mapk family | 5 |
active caspase | 5 |
previous findings | 5 |
right panel | 5 |
granulocyte macrophage | 5 |
expression profiles | 5 |
older patients | 5 |
cognitive decline | 5 |
patients suffered | 5 |
five datasets | 5 |
cellular kinetics | 5 |
intravital imaging | 5 |
potentially important | 5 |
marrow stromal | 5 |
vivo experiments | 5 |
mucociliary epithelium | 5 |
causative bacteria | 5 |
marrow chimeras | 5 |
eines ptsd | 5 |
operated control | 5 |
organoid model | 5 |
mixed venous | 5 |
cruz biotechnology | 5 |
venous pressure | 5 |
prolonged mechanical | 5 |
human recombinant | 5 |
crystal structure | 5 |
human development | 5 |
cross talk | 5 |
cellular processes | 5 |
results demonstrate | 5 |
survival benefit | 5 |
data support | 5 |
murine sepsis | 5 |
precision medicine | 5 |
infection causes | 5 |
surface tension | 5 |
protective strategies | 5 |
mean duration | 5 |
disease progression | 5 |
enteral diet | 5 |
possible therapeutic | 5 |
reduce lung | 5 |
well established | 5 |
health organization | 5 |
randomized clinical | 5 |
placebo group | 5 |
diseases including | 5 |
retrospective cohort | 5 |
parenteral administration | 5 |
ards patient | 5 |
intubated patients | 5 |
right ventricular | 5 |
cyclic adenosine | 5 |
induced systemic | 5 |
pars expression | 5 |
ill adults | 5 |
predisposing factors | 5 |
isth overt | 5 |
mice via | 5 |
guinea pigs | 5 |
tissue culture | 5 |
serum procalcitonin | 5 |
key component | 5 |
tissue oxygen | 5 |
process following | 5 |
study conducted | 5 |
exudative phases | 5 |
specifi city | 5 |
whole lung | 5 |